Clinical Trials

Brain Cancer (Glioblastoma Multiforme)


An open-label phase I trial to study side effects and the best dose of AT-101 to give with temozolomide with or without radiation therapy

Where is this study being conducted?

This study is being conducted at multiple sites within the United States.

Who is conducting the trial?

This trial is being sponsored by Ascenta Therapeutics, Inc., and the National Cancer Institute.

Who can participate?

What is AT-101?

AT-101 activates a pathway inside cancer cells resulting in the death of those cells. It is given by mouth in the form of pills.

What is temozolomide?

Temozolomide is a chemotherapy agent.

What do I do if I am interested in participating in this clinical trial?

 Contact your physician. Your physician will be able to advise you about participating.

Trial Identification Number

NCT00390403

For more information on this trial, please visit www.clinicaltrials.gov